Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma, Large B-Cell, Diffuse × navitoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 178 Cyclophosphamide 144 Etoposide 76 Vincristine 65 Prednisone 65 Doxorubicin 64 Peripheral Blood Stem Cell Transplantation 49 Filgrastim 49 Cytarabine 40 Radiotherapy 38 Lenalidomide 37 fludarabine phosphate 36 Mycophenolic Acid 33 Methotrexate 32 Tacrolimus 29 Busulfan 28 Ifosfamide 27 Gemcitabine 27 Carmustine 27 Melphalan 26 Cyclosporine 26 Whole-Body Irradiation 24 Antilymphocyte Serum 23 zanubrutinib 22 Methylprednisolone 19 polatuzumab vedotin 18 Dexamethasone 18 Cisplatin 18 Carboplatin 18 Oxaliplatin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01423539 2016-11-02

NAVIGATE

Genentech, Inc.

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡